FMP
IceCure Medical Ltd
ICCM
NASDAQ
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
1.24 USD
-0.03 (-2.42%)
Historical Prices
From:
To:
About
ceo
Mr. Eyal Shamir
sector
Healthcare
industry
Medical - Devices
exchange
NASDAQ
Description
IceCure Medical Ltd, a medical device company, engages in the research, development, and commercialization of medical devices for cryoablation (freezing) of tumors in the human body. It offers ProSense system, a cryoablation solution for the treatment of breast tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.
CIK
0001584371
ISIN
IL0011224156
CUSIP
M53071136
Address
7 Ha’Eshel Street
Phone
972 4 623 0333
Country
IL
Employee
64
IPO Date
Aug 26, 2021
Financial Statement
Earnings
ICCM Financial Summary
CIK
0001584371
Exchange
NASDAQ
Industry
Medical - Devices
Sector
Healthcare
CUSIP
M53071136
ISIN
IL0011224156
Country
IL
Price
1.24
Beta
2.31
Volume Avg.
304.44k
Market Cap
70.15M
Shares
-
52-Week
0.48-1.66
DCF
-0.32
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-4.13
P/B
-
Website
https://www.icecure-medical.com
Upgrades and Downgrades
We are unable to load the data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest ICCM News
Alex Lavoie
Mar 27, 2025
IceCure Medical Ltd. (NASDAQ: ICCM) Financial Performance Ov...
IceCure Medical Ltd. (NASDAQ: ICCM) is a company that focuses on developing minimally-invasive cryoablation technology for the destruction of tumors. This innovative approach offers an alternative to traditional surgical methods, aiming to provide effective treatment with reduced recovery times. As a player in the medical technology sector, ICCM competes with other companies that offer similar non-invasive cancer treatment solutions. On March 27, 2025, ICCM reported its earnings, revealing an e...
Zacks Investment Research
Aug 20, 2024
IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Es...
IceCure Medical Ltd. (ICCM) came out with a quarterly loss of $0.06 per share versus the Zacks Consensus Estimate of a loss of $0.07.
PRNewsWire
Aug 13, 2024
IceCure Medical to Report Second Quarter 2024 Financial & Op...
CAESAREA, Israel , Aug. 13, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release with its financial and operational results as of and for the six months ended June 30, 2024 before the Nasdaq Stock Market opens on Tuesday, August 20, 2024.
Zacks Investment Research
Jul 11, 2024
IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint
IceCure Medical Ltd. ICCM recently announced the publication of data from an independent study evaluating its ProSense cryoablation system in the peer-reviewed journal — Cancers.
Zacks Investment Research
Jul 3, 2024
IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod
IceCure Medical Ltd ICCM recently announced that it has received marketing authorization from the FDA for its next-generation single probe cryoablation system, XSense Cryoablation System with CryoProbes.
Zacks Investment Research
Jun 4, 2024
IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Up...
IceCure Medical (ICCM) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PRNewsWire
May 21, 2024
IceCure Medical to Report First Quarter 2024 Financial & Ope...
CAESAREA, Israel, May 21, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release containing its financial and operational results as of and for the three months ended March 31, 2024 before the Nasdaq Stock Market opens on Tuesday, May 28, 2024.
PRNewsWire
May 21, 2024
IceCure Medical to Report First Quarter 2024 Financial & Ope...
CAESAREA, Israel , May 21, 2024 /PRNewswire/ -- IceCure Medical Ltd. (Nasdaq: ICCM) ("IceCure" or the "Company"), developer of the ProSense® System, a minimally-invasive cryoablation technology that destroys tumors by freezing as an alternative to surgical tumor removal, announced today that it will issue a press release containing its financial and operational results as of and for the three months ended March 31, 2024 before the Nasdaq Stock Market opens on Tuesday, May 28, 2024.
